Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation

BACKGROUND: Renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation is a very dangerous malignant tumor and extremely rare in clinical practice. In general, these tumors with a dismal prognosis, and there is no standard treatment. CASE PRESENTATION: In this case, an 81-year-old...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Shibin, Yu, Chenhao, Wang, Chongwei, Ding, Guoqing, Cheng, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623047/
https://www.ncbi.nlm.nih.gov/pubmed/36330483
http://dx.doi.org/10.3389/fonc.2022.969106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623047/
https://www.ncbi.nlm.nih.gov/pubmed/36330483
http://dx.doi.org/10.3389/fonc.2022.969106

Ejemplares similares